Erudio Healtherudio.com
Drug
Exemestane trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying exemestane: FOURLIGHT-1. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 12 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| FOURLIGHT-1 NCT06105632 · Pfizer | HR-positive/HER2-negative advanced/metastatic breast cancer after CDK4/6 inhibitor-based therapy | Phase 2 | 186 | 60 | Standard | Nov 13, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| PATINA NCT02947685 · Alliance Foundation Trials, LLC. DeepView → | hormone receptor-positive, HER2-positive metastatic breast cancer | Phase 3 | Deep | View | |||
| EMBER-3 NCT04975308 · Eli Lilly and Company DeepView → | ER+, HER2- advanced breast cancer | Phase 3 | Deep | View | |||
| TAILORx NCT00310180 · National Cancer Institute (NCI) DeepView → | hormone receptor-positive HER2-negative node-negative breast cancer | Phase 3 | Deep | View | |||
| RxPONDER NCT01272037 · National Cancer Institute (NCI) DeepView → | Not given | Phase 3 | Deep | View | |||
| evERA NCT05306340 · Genentech, Inc. DeepView → | ER-positive, HER2-negative locally advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| CAMBRIA-2 NCT05952557 · AstraZeneca DeepView → | ER+/HER2- early breast cancer | Phase 3 | Deep | View | |||
| BOLERO-2 NCT00863655 · Novartis Pharmaceuticals DeepView → | estrogen receptor-positive locally advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| EMBER-4 NCT05514054 · Eli Lilly and Company DeepView → | ER+, HER2- early breast cancer | Phase 3 | Deep | View | |||
| CAMBRIA-1 NCT05774951 · AstraZeneca DeepView → | ER+/HER2- early breast cancer | Phase 3 | Deep | View | |||
| TREAT ctDNA NCT05512364 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | ER+/HER2- breast cancer with ctDNA relapse | Phase 3 | Deep | View | |||
| TRAK-ER NCT04985266 · Royal Marsden NHS Foundation Trust StandardView → | ER-positive HER2-negative breast cancer with molecular relapse | Phase 2 | Standard | View | |||
| EvoPAR-Breast01 NCT06380751 · AstraZeneca StandardView → | first-line BRCA1/BRCA2/PALB2-mutated HR-positive HER2-negative advanced breast cancer | Phase 3 | Standard | View | |||